InsidersTradesSigma
Total declarations
Companies
▲ Purchases (10 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
10
Disclosed sells
0
T+90 hit rate
40%
T+90 mean return
-9.6%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Innoviva, Inc.. Officer active across 2 companies, notably Entasis Therapeutics Holdings Inc.. Aggregated, 10 reports have been recorded. Breakdown: 10 buys · 0 sell. Total volume traded: €121m. History available since 3 May 2021. The latest transaction was filed on 8 July 2022 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations10 total
11,671,662 shares@ US$2.2043.4% of flowCommon StockSEC:0001140361-22-025957:0
Ideal exit: 4 Apr 2023 (T+270)
5,385,208 shares@ US$5.008.23% mcap38.7% of flowCommon StockSEC:0001567619-22-007861:0
Ideal exit: 26 Dec 2022 (T+270)
3,614,792 shares@ US$5.005.35% mcap25.2% of flowCommon StockSEC:0001567619-22-003750:0
Ideal exit: 6 Nov 2022 (T+270)
3,614,792 shares@ US$5.0082.2% of flowCommon StockSEC:0001567619-22-003750
Ideal exit: 6 Nov 2022 (T+270)
1,212,122 shares@ US$3.301.16% mcap5.5% of flowCommon StockSEC:0001567619-21-019063:0
Ideal exit: 26 Jul 2022 (T+270)
1,212,122 shares@ US$3.305.5% of flowCommon StockSEC:0001567619-21-019063
Ideal exit: 26 Jul 2022 (T+270)
6,268,975 shares@ US$2.0031.2% of flowCommon StockSEC:0001567619-21-012030:0
Ideal exit: 8 Mar 2022 (T+270)
6,268,975 shares@ US$2.0017.7% of flowCommon StockSEC:0001567619-21-012030
Ideal exit: 8 Mar 2022 (T+270)
3,731,025 shares@ US$2.0018.8% of flowCommon StockSEC:0001567619-21-010772
Ideal exit: 28 Jan 2022 (T+270)
3,731,025 shares@ US$2.0018.8% of flowCommon StockSEC:0001567619-21-010772:0
Ideal exit: 28 Jan 2022 (T+270)
10 of 10 declarations
About Innoviva, Inc.
Innoviva, Inc. is a director and insider at Entasis Therapeutics Holdings Inc. and Armata Pharmaceuticals, Inc.
